Pfizer Inc.(NYSE:PFE) would cut its yearly tax bill by hundreds of millions of dollars if it buys rival AstraZeneca PLC, but thousands of Pfizer shareholders face a tax hit if a deal goes through. Pfizer Inc.(NYSE:PFE) net profit margin is 81.20% and weekly performance is -4.76%. On last trading day company shares ended up $29.03. Analysts mean target price for the company is $33.97. Pfizer Inc. (NYSE:PFE) distance from 50-day simple moving average (SMA50) is -6.64%.
AstraZeneca plc (ADR) (NYSE:AZN) last posted its quarterly earnings results on Thursday. The company reported $1.17 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.23 by $0.06. The company had revenue of $6.42 billion for the quarter, during the same quarter last year, the company posted $1.41 earnings per share. AstraZeneca plc (ADR)’s revenue was up .5% compared to the same quarter last year. Analysts expect that AstraZeneca plc will post $4.23 EPS for the current fiscal year. AstraZeneca plc (ADR) (NYSE:AZN) shares fell -1.91%in last trading session and ended the day on $77.24. AZN Gross Margin is 79.80% and its return on assets is 3.70%AstraZeneca plc (ADR)(NYSE:AZN) } quarterly performance is 24.62%.
AiCuris and Merck & Co., Inc.(NYSE:MRK) known as MSD , announced the publication of results from a Phase 2 clinical trial evaluating the safety and efficacy of letermovir, an investigational, oral antiviral agent for the prevention of human cytomegalovirus (CMV) infection in patients receiving bone marrow transplant. The results published in the latest issue of the New England Journal of Medicine (NEJM) show that letermovir in CMV-seropositive allogeneic human blood precursor cell recipients (bone marrow transplant patients) met the study’s two primary efficacy endpoints. Merck plans to conduct a Phase 3 trial of letermovir, also known as AIC246 or MK-8228, starting in the first half of 2014.Merck & Co., Inc.(NYSE:MRK) shares moved up 0.69% in last trading session and was closed at $55.21, while trading in range of $54.40 – $55.71. Merck & Co., Inc. (NYSE:MRK) year to date (YTD) performance is 11.18%.
8 MAY 2014 Bristol-Myers Squibb Co (NYSE:BMY) announced that it will present new data from investigating studies of its immuno therapies during the American Society of Clinical Oncology’s 50th annual meeting to be held in Chicago between May 30 and June 3.Bristol-Myers Squibb Co(NYSE:BMY) ended the last trading day at $51.18. Company weekly volatility is calculated as 2.12%and price to cash ratio as 12.02. Bristol-Myers Squibb Co (NYSE:BMY) showed a positive weekly performance of 2.77%.
Leave a Reply